International Journal of Molecular and Cellular Medicine最新文献

{"title":"Anti-tumor Effects of Curcumin and ABT-737 in Combination Therapy for Glioblastoma in Vivo.","authors":"Zahra Sadat Miri, Hossein Bagheri, Alireza Amani, Hadi Karami","doi":"10.22088/IJMCM.BUMS.14.1.552","DOIUrl":"10.22088/IJMCM.BUMS.14.1.552","url":null,"abstract":"<p><p>The resistance of tumor cells to ABT-737 can be attributed to alterations in the equilibrium of Bcl-2 family proteins. In this study, the effect of curcumin on the Mcl-1expression and the sensitivity of glioblastoma cells to ABT-737 were examined. Trypan blue assay and colony formation assay were performed to explore the effects of treatments on cell proliferation. MTT assay was performed to measure cytotoxicity. Cell migration was determined using a wound healing assay. Cell apoptosis was measured by Hoechst 33342 staining, ELISA cell death, and caspase-3 activity assay. The expression levels of Mcl-1 mRNA were also tested by qRT-PCR. Our results revealed that combination therapy significantly lowered the IC₅₀ value and synergistically decreased the colony formation and migration, cell survival and growth of glioblastoma cells compared with curcumin or ABT-737 alone. Treatment with curcumin clearly inhibited the expression of Mcl-1 mRNA. Moreover, suppression of Mcl-1 mRNA by curcumin was associated with enhancement of apoptosis induced by ABT-737. In conclusion, curcumin has the ability to inhibit the cell proliferation and migration, and activate the intrinsic pathway of apoptosis. Moreover, it can enhance the sensitivity of glioblastoma cells to ABT-737 by suppressing the expression of Mcl-1.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"552-566"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Down Expression of Zyxin is Associated with Down Expression of p53 in Colorectal Cancer.","authors":"Hossein Mohammadi, Ebrahim Shakiba, Rezvan Rostampour, Kiana Bahremand, Mohammad Taghi Goodarzi, Homayoon Bashiri, Khadijeh Najafi Ghobadi, Soheila Asadi","doi":"10.22088/IJMCM.BUMS.14.1.462","DOIUrl":"10.22088/IJMCM.BUMS.14.1.462","url":null,"abstract":"<p><p>Colorectal cancer (CRC), which is among the most prevalent cancers worldwide, is caused by environmental and genetic factors. It has been shown that the <i>p53</i> gene is associated with CRC pathogenesis; moreover, Zyxin (ZYX) may play a role in <i>p53</i> level and activity. Therefore, the present research aimed to investigate the levels of P53 and <i>ZYX</i> genes and proteins in CRC tumor samples. Cancerous tissues (n=31) and matched non-cancerous tissues (n=31) were randomly obtained from 31 patients with CRC. Total RNA was extracted using RNXplus, and gene expressions were assessed by Real-time PCR. Furthermore, the Western blot technique was used to investigate the expression of ZYX and P53 proteins. The obtained results revealed that the expression of <i>ZYX</i> and <i>p53</i> genes in cancerous tissues showed no significant difference compared to matched non-cancerous tissues. On the other hand, measuring protein expression using the Western blotting technique indicated that the ZYX (P=0.0081) and <i>p53</i> (P=0.0065) expression in tumor tissues significantly decreased compared to those in matched non-cancerous tissues. Correlation analysis indicated a significant correlation between ZYX and P53 proteins (r=0.746, P=0.013). Based on our findings, ZYX might have a suppressive function in CRC and is associated with P53.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"461-471"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Curcumin on Biofilm Production and Associated Gene in Multidrug-Resistant <i>Acinetobacter baumannii</i> Isolated from Hospitalized Patients.","authors":"Kasra Javadi, Mohammad Hossein Ahmadi, Mehdi Rajabnia, Mehrdad Halaji","doi":"10.22088/IJMCM.BUMS.14.1.567","DOIUrl":"10.22088/IJMCM.BUMS.14.1.567","url":null,"abstract":"<p><p>Multi-drug-resistant (MDR) <i>Acinetobacter</i> <i>baumannii</i> has become a major global healthcare concern due to its opportunistic infections and high antibiotic resistance. This investigation is intended to investigate curcumin's potential anti-bacterial and antibiofilm impacts on MDR <i>A</i>. <i>baumannii</i> and to present a promising strategy for fighting against infections caused by this pathogen. This cross-sectional investigation comprised 34 MDR <i>A</i>. <i>baumannii</i> clinical isolates. The Kirby-Bauer disc diffusion method evaluated the sensitivity of isolates to multifaceted anti-bacterial agents. The microdilution broth method quantified curcumin's minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC). The efficacy of curcumin in inhibiting MDR <i>A</i>. <i>baumannii</i> biofilm was assessed via 96-well microtiter plates. The expression of the biofilm-associated protein (<i>bap</i>) gene was evaluated by employing quantitative real-time PCR (qRT-PCR). Within the 34 MDR <i>A</i>. <i>baumannii</i> isolates, the highest resistance was noted for trimethoprim/sulfamethoxazole and ciprofloxacin, with all 34 isolates (100%) indicating resistance. The lowest resistance was noted for ampicillin/sulbactam, with 22 isolates (64.7%) exhibiting resistance. The MICs of curcumin ranged from 0.625 to 2.5 mg/ml, while the MBCs varied between 1.25 to 5 mg/ml. Curcumin reduced biofilm formation by 25% to 91%, depending on the concentration. In contrast to the untreated control, the average relative activity of the <i>bap</i> gene in MDR <i>A. baumannii</i> isolates declined by 62.07%. The findings indicate that curcumin demonstrates antimicrobial and anti-biofilm activities against MDR <i>A</i>. <i>baumannii</i>. The downregulation noted in the <i>bap</i> gene further supports the curcumin's anti-biofilm impact.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"567-575"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elucidating the Role of LINC01980 in Laryngeal Cancer: From Expression Profiling to Regulatory Network Prediction.","authors":"Masoumeh Razipour, Zeinab Jamali, Elham Ghadami, Saeed Sohrabpour, Leyla Sahebi, Abbas Shakoori","doi":"10.22088/IJMCM.BUMS.14.1.517","DOIUrl":"10.22088/IJMCM.BUMS.14.1.517","url":null,"abstract":"<p><p>Laryngeal squamous cell carcinoma (LSCC) remains a significant global health challenge despite advances in treatment. This study investigated the involvement of LINC01980, a long non-coding RNA, in LSCC pathogenesis. We conducted an integrative analysis of transcriptomic data sourced from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases to identify genes that are differentially expressed in LSCC. LINC01980 expression was evaluated in 32 matched pairs of advanced-stage LSCC and adjacent normal tissues using quantitative real-time PCR (qRT-PCR). The potential competing endogenous RNA (ceRNA) network involving LINC01980 was explored through bioinformatics analyses. Findings revealed significant upregulation of LINC01980 in LSCC tissues compared to normal adjacent tissues (<i>p</i> < 0.0001), with elevated expression in 78.125% of tumor samples. Receiver Operating Characteristic (ROC) curve analysis demonstrated LINC01980's potential as a diagnostic biomarker (AUC = 0.7666, <i>p</i> = 0.0002). While no significant correlations were found between LINC01980 expression and clinicopathological features, bioinformatics analyses identified potential LINC01980/ miRNA/ mRNA regulatory network involving hsa-let-7e-5p and hub gene MMP9. This study provides insights into LINC01980's role in LSCC and suggests its potential as a diagnostic biomarker and therapeutic target. Further research is warranted to elucidate the precise molecular mechanisms of LINC01980 in LSCC progression.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"517-532"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment.","authors":"Khatereh Anbari, Koroush Ghanadi","doi":"10.22088/IJMCM.BUMS.14.1.576","DOIUrl":"10.22088/IJMCM.BUMS.14.1.576","url":null,"abstract":"<p><p>By 2040 the burden of colorectal cancer will increase to 3.2 million new cases per year and 1.6 million deaths per year. This highlights the importance of improving preventive measures and treatment strategies. This piece concisely overviews the latest therapeutic and diagnostic approaches for colorectal cancer. In 2019, factors such as low milk intake, smoking, insufficient calcium consumption, and alcohol use had a significant impact on colorectal cancer DALYs worldwide. A comprehensive search was conducted in December 2023 using keywords related to drugs, therapeutic agents, colorectal cancer, diagnostic methods, epidemiology, and novel therapeutic approaches in the PubMed and Scopus databases. Initially, 325 articles were identified based on titles, abstracts, and publication dates. After removing duplicates, 170 unique articles were included. Medications like Nimotuzumab, Cetuximab, and Panitumumab target the Epidermal Growth Factor Receptor (EGFR), which EGF activates. HER2, activated by ligands, is the focus of drugs like Trastuzumab and Pertuzumab. The PD-1/PD-L1 and CTLA-4 pathways, as the immune checkpoints, which involve T cells, are targeted by medications like Ipilimumab. Adoptive cell therapy, including CAR-T cell therapy, TCR modification, and enhancing T cell activity through tumor-infiltrating lymphocytes, is used to combat cancer cell growth. In medical advancements, adoptive cell transfer therapy (ACT) and exosomes in the tumor immune microenvironment (TME) are notable treatment methods that boost the immune system. HIF1A-AS1, CRNDE-h, NEAT1, ZFAS1, and GAS5, along with IGFBP-2, have demonstrated significant CRC diagnostic capacity. Compared to CRC patients with low HIF1A-AS1 expression, individuals with high expression levels were linked to a worse 5-year survival rate.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"576-605"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SLC7A11 Inhibitors Represent a Promising Therapeutic Target by Facilitating the Induction of Ferroptosis in Breast Cancer.","authors":"Rojin Azizi, Hanan Hassan Ahmed, Radhwan Abdul Kareem, Waam Mohammed Taher Waam, Mariem Alwan, Mahmood Jasem Jawad, Atheer Khdyair Hamad, Satinik Darzi","doi":"10.22088/IJMCM.BUMS.14.1.496","DOIUrl":"10.22088/IJMCM.BUMS.14.1.496","url":null,"abstract":"<p><p>It is predicted with near certainty that an estimated 310,720 women will be diagnosed with invasive breast carcinoma in 2024, while the number of men will be significantly lower at around 2,800, highlighting the alarming prevalence of this cancer across the sexes. The Solute Carrier Family 7 Member 11(SLC7A11) gene is vital for the exchange of extracellular cystine for glutamate at a 1:1 ratio and its expression is significantly increased in various tumors. Numerous research studies have shown that SLC7A11 expression is fine-tuned at several levels, contributing to its pharmacological functions in tumors, such as maintaining cellular redox balance, promoting cell proliferation, and influencing ferroptosis. Many studies suggest that reducing SLC7A11 expression and activity may be beneficial for cancer treatment, making it a promising target for therapy. However, recent findings also suggest that inhibiting SLC7A11 in certain scenarios may increase the survival of cancer cells and promote drug resistance. This review begins with a brief overview of the properties of SLC7A11, including its structural features and physiological functions, followed by a summary of its potential regulators. We then delve deeper into its role in cancer, particularly breast cancer, and explore the relationships between SLC7A11 and ferroptosis, proliferation, metastasis, and therapeutic resistance. Consequently, more customized therapeutic approaches should be considered when targeting SLC7A11 in the context of breast cancer. Thus, high expression of SLC7A11 is associated with poor prognosis in breast cancer, and various inhibitors have been identified that can effectively target this transporter. Innovative therapeutic strategies, including immunotherapies targeting SLC7A11, can potentially reduce tumor growth and metastasis in breast cancer models.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"496-516"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gambogic Acid Mitigates Nephropathy by Inhibiting Oxidative Stress and Inflammation in Diabetic Rats.","authors":"Ruttiya Thongrung, Sarawut Lapmanee, Penjai Thongnuanjan Bray, Patlada Suthamwong, Suwaporn Deandee, Kanjana Pangjit, Chaowalit Yuajit","doi":"10.22088/IJMCM.BUMS.14.1.448","DOIUrl":"10.22088/IJMCM.BUMS.14.1.448","url":null,"abstract":"<p><p>Diabetic nephropathy is a leading cause of end-stage renal disease globally, with limited treatment options to prevent its progression. Gambogic acid (GA), a xanthone isolated from Garcinia hanburyi, has shown notable anti-oxidative, anti-inflammatory, and anti-proliferative properties. This study aimed to assess GA's renoprotective effects in a model of diabetic nephropathy mediated by low dose streptozotocin (STZ) combined with a high-fat diet, focusing on its potential to reduce oxidative stress and inflammation. Control-treated vehicle and STZ/high-fat diet-mediated diabetic rats were administered either the vehicle or 3 or 6 mg/kg of GA to assess its effects on renal inflammation, fibrosis, and oxidative stress. Renal histological changes were assessed, and markers for inflammation and oxidative stress, including I-κBα, p-p38/MAPK, and p-p65NF-κB pathways, were measured to explore the mechanisms of GA. Diabetic rats showed significant renal dysfunction, structural damage, and increased inflammation and fibrosis. Treatment with GA markedly improved renal structure and function. GA also reduced oxidative stress, increased I-κBα expression, and inhibited key signaling pathways, specifically p-p38/MAPK and p-p65NF-κB, involved in cellular inflammation. GA exhibits promising renoprotective effects in diabetic nephropathy by reducing oxidative stress and inflammation, supporting its potential as a natural therapeutic agent for diabetic renal disease.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"448-461"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with Various Pathway Signaling.","authors":"Mahyar Haki, Reihaneh Bayat","doi":"10.22088/IJMCM.BUMS.14.1.533","DOIUrl":"10.22088/IJMCM.BUMS.14.1.533","url":null,"abstract":"<p><p>Breast cancer encompasses a diverse array of conditions classified as hormone receptor-positive, human epidermal growth factor receptor 2-positive, and triple-negative breast cancer subtypes, dictating treatment approaches. The therapeutic strategies commonly involve addressing estrogen receptors (ER) and HER2, which have exhibited efficacy in managing cancer. Nevertheless, the prevalence of resistance to these therapies, whether inherent or acquired, persists despite the introduction of novel treatment modalities. Progress in comprehending the biology of tumors has facilitated the identification of fresh targets, such as inhibitors targeting different pathways like phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR), cell-cycle regulation, heat shock protein, and epigenetic pathways, demonstrating encouraging outcomes in clinical experiments. For example, the mTOR inhibitor everolimus has been sanctioned for ER+ breast cancer and resistance to aromatase inhibitors in the advanced or metastatic phase. Triple-negative breast cancer, characterized by the absence of estrogen receptors, progesterone receptors, and HER2, currently lacks established targeted therapies. While poly (ADP-ribose) polymerase inhibitors exhibit effectiveness in BRCA-related cancers, their efficiency in addressing triple-negative breast cancer residues is uncertain. This paper furnishes a comprehensive outline of the principal targeted therapies presently employed or under exploration for breast cancer treatment within the three clinical subsets.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"533-551"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible Trace of HTLV-1 Virus in Modulation of Cbl-b, ITCH, and PP2A Suppressor Genes.","authors":"Atefeh Bahavar, Abdolvahab Moradi, Hamed Mohammadi, Mehdi Norouzi, Sara Khodayar, Sayed-Hamidreza Mozhgani, Alijan Tabarraei","doi":"10.22088/IJMCM.BUMS.14.1.472","DOIUrl":"10.22088/IJMCM.BUMS.14.1.472","url":null,"abstract":"<p><p>For almost 40 years, human T-lymphotropic virus type 1 (HTLV-1) has posed a persistent challenge in managing the major diseases associated with HTLV-1. Intracellular inhibitors are critical regulators of T cell activation, and their function can be influenced by viruses. Because of less studied aspects of HTLV-1 in T cell activation, we evaluated three suppressor genes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and asymptomatic carriers (ACs). Thirty samples were collected from three groups from 10/09/2022 to 03/27/2024. To confirm all the samples, ELISA and PCR tests were done. The isolation of peripheral blood mononuclear cells (PBMCs), RNA extraction, and cDNA synthesis were conducted. Subsequently, the expression of <i>Tax trans-activator, HTLV-1 bZIP factor (HBZ), protein phosphatase 2 A (PP2A),</i> and two E3 ligases, including <i>Casitas B</i> <i>lymphoma-b (Cbl-b)</i> and <i>itchy E3 Ubiquitin protein ligase (ITCH),</i> was measured via Real-time PCR. This survey showed a significant increase in ITCH among individuals with HAM/TSP and ACs compared to the healthy group. The <i>PP2A</i> mRNA expression level was upregulated in the ACs; in contrast, the expression levels were approximately similar in the HAM/TSP and healthy groups. Also, the mean expression level of <i>Cbl-b</i> was higher in the ACs than in the other groups; however, it was not statistically significant. Our findings demonstrated that the intercellular suppressor genes could be dysregulated during the HTLV-1 infection, probably as part of the virus's strategic goals. The findings can be helpful for future investigation in the diagnosis and treatment area.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"472-482"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of the Antimicrobial and Antibiofilm Activity of AH Plus Sealer with Chitosan Nanoparticles and Arginine against Enterococcus faecalis and Candida albicans.","authors":"Elham Khoshbin, Hamed Karkehabadi, Mohammad Yousef Alikhani, Amirhossein Rajabnia","doi":"10.22088/IJMCM.BUMS.14.1.483","DOIUrl":"10.22088/IJMCM.BUMS.14.1.483","url":null,"abstract":"<p><p>The success of endodontic treatments can be significantly impaired by persistent microbial pathogens, especially <i>Enterococcus</i> <i>faecalis</i> (<i>E</i>. <i>faecalis</i>) and <i>Candida</i> <i>albicans</i> (<i>C</i>. <i>albicans</i>). The aim of this study was to investigate how the incorporation of chitosan nanoparticles (CsNPs) and arginine (Arg) can enhance the antimicrobial and antibiofilm efficacy of AH Plus, a widely used epoxy resin-based root canal sealer. The CsNPs were synthesized by ionotropic gelation and assessed for their size, morphology, chemical structure, and cytotoxicity. The antimicrobial effectiveness of the modified sealers was evaluated against <i>E</i>. <i>faecalis</i> and <i>C</i>. <i>albicans</i> by determining the minimum inhibitory concentration, minimum bactericidal concentration, minimum fungicidal concentration, and agar diffusion method. Additionally, antibiofilm activity was assessed using a microtiter plate assay. Characterization of the CsNPs revealed an average size of 144 ± 12.8 nm by scanning electron microscopy and 182.4 nm by dynamic light scattering with a zeta capacitance of +49.2 mV. CsNPs maintained more than 68% cell viability at 625 μg/mL after 24 and 48 hours. Adding CsNPs and Arg significantly enhanced the impact of AH Plus sealer on antimicrobial and antibiofilm, especially at elevated additive concentrations. This study suggests that AH Plus sealers containing CsNPs and Arg may offer a promising approach to enhance endodontic treatment outcomes by efficiently combating resistant root canal infections.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 1","pages":"483-495"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}